

13 November 2017

Philip Owens Appointed CEO of Omni Innovation

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its ~40% portfolio company, Omni Innovation, the medical technology company focused on medical nutrition.

Appointment of Mr Philip Owens

Omni Innovation advises that the Board of Omni Innovation has elevated Mr Philip Owens (B.Sc., Grad Dip Psych.) to the position of Chief Executive Officer of the Company, effective immediately. Mr Owens brings over 20 years of operational and strategic leadership experience to the role and was most recently the Company's Chief Operating Officer after joining Omni Innovation in 2016.

Mr Owens was integral in overseeing the recent licencing deal between the Company and Eagle Health Holdings Limited. As CEO he will continue overseeing this important relationship as the rollout into China and Hong Kong proceeds, as well as focussing on the development of new product lines for the Company and working with Faulding® on the development of the market for Faulding® GlucoControl™ locally.

Previously, Mr Owens has launched and incubated businesses around the globe and has a demonstrable track record of creating exceptional business strategies, structures, processes and results, including doubling an established business to more than \$2 billion (AUD) in sales.

Mr Owens has worked in a variety of roles in the health industry, notably ten years with Bayer Health Care in various roles. From 2008 to 2010, he was the Global Brand Team Leader based in Germany. During his time in the role he successfully oversaw global P&L targets, including exceeding sales of 1.2 Billion Euros, managed a marketing budget of 300 Million Euros and a research and development budget of 56 Million Euros.

Arie Nudel, the outgoing CEO, will continue in a revised role with the Company focussing on the Company's expansion into the lucrative US market.

About Omni Innovation

Omni Innovation creates unique and specialised medical nutrition products that can be used by people with chronic and lifestyle diseases. Omni's products are independently validated and supervised by Omni's expert collaborator network to ensure that customers have safe, effective and clinically tested products that provide benefit with scientific backing.

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in medical nutrition companies. EVE is an investment partner that wants to help build ground breaking and enduring technology with a preference for companies that have global scale.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

For more information:

Ben Rohr

Investment Director

+61 8 6465 5500

benr@eveinvestments.com.au